IL-35-Mediated Immunotherapy for Type I and Autoimmune Diabetes Mellitus

The Hidden Risks of Sitting for 8+ Hours

IL-35 therapy targets immune responses, offering hope for Type 1 Diabetes patients.

How IL-35 Works?

IL-35 regulates T-cells to reduce inflammation in autoimmune diabetes.

Benefits for Type 1 Diabetes

May improve insulin levels by balancing immune reactions in pancreatic cells.

Advances in Autoimmune Therapy

IL-35 offers a novel approach, reducing dependency on traditional treatments.

Targeting Immune Responses

Modulates immune cells to prevent destructive attacks on pancreatic beta cells.

Potential for Widespread Use

Could benefit other autoimmune conditions, not just diabetes.

The Future of IL-35 in Medicine

Research is ongoing, aiming to make IL-35 treatments widely available.